DOXYCYCLINE HYCLATE (doxycycline hyclate) by Pfizer is mechanism of action: doxycycline has been shown to inhibit collagenase activity in vitro . Approved for pocket depth in patients with adult periodontitis. First approved in 2006.
Drug data last refreshed 20h ago
Mechanism of Action: Doxycycline has been shown to inhibit collagenase activity in vitro . Additional studies have shown that doxycycline reduces the elevated collagenase activity in the gingival crevicular fluid of patients with adult periodontitis. The clinical significance of these findings is…
Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate
Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
Worked on DOXYCYCLINE HYCLATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo